Table 3 Hazard ratios (HR) and 95% confidence interval (95% CI) for colorectal cancer (CRC) specific survival for all cases, the physically inactive, and the physically active, adjusted for stage (categorical), degree of differentiation (categorical), age and sex, per cent fat, BMI, and insulin‐like growth factor 1/insulin‐like growth factor binding protein 3 (IGF‐1/IGFBP‐3).
| HR (95% CI) comparing quartile of plasma level with quartile 1 | HR per increase of 1 SD in hormone level | |||
|---|---|---|---|---|
| Q2 | Q3 | Q4 | ||
| All cases | ||||
| IGF‐1 per 8.5 nmol/l | 1.29 (0.80–2.08) | 1.16 (0.71–1.90) | 1.10 (0.62–1.94) | 1.01 (0.89–1.14) p = 0.90 |
| IGFBP‐3 per 26.2 nmol/l | 0.87 (0.53–1.42) | 0.99 (0.60–1.64) | 0.72 (0.41–1.24) | 0.87 (0.71–1.06) p = 0.16 |
| Physically inactive | ||||
| IGF‐1per 8.5 nmol/l | 1.28 (0.70–2.34) | 0.93 (0.49–1.75) | 1.36 (0.67–2.75) | 1.08 (0.85–1.37); p = 0.54 |
| IGFBP‐3 per 26.2 nmol/l | 1.04 (0.56–1.92) | 1.22 (0.64–2.33) | 1.17 (0.59–2.32) | 1.04 (0.82–1.32); p = 0.73 |
| Physically active | ||||
| IGF‐1per 8.5 nmol/l | 0.84 (0.35–2.02) | 1.36 (0.52–3.53) | 0.90 (0.28–2.85) | 0.90 (0.55–1.45); p = 0.65 |
| IGFBP‐3 per 26.2 nmol/l | 0.48 (0.19–1.19) | 0.50 (0.20–1.28) | 0.23 (0.08–0.73) | 0.52 (0.33–0.83); p = 0.006 |
Standard deviation (SD) for IGF‐1 is 8.5 nmol/l; SD for IGFBP‐3 is 26.2 nmol/l.
Quartiles are based on all 443 cases.